After selection against FcRIIa by fluorescence-activated cell sorting (FACS), a double Fc mutant isolate (S298G/T299A) in an aglycosylated form showed threefold stronger binding as compared to the WT and variants with single mutation, which indicates that this glycosylation of N297 is not a strict requirement for the interaction of Fc with FcRIIa (61)

After selection against FcRIIa by fluorescence-activated cell sorting (FACS), a double Fc mutant isolate (S298G/T299A) in an aglycosylated form showed threefold stronger binding as compared to the WT and variants with single mutation, which indicates that this glycosylation of N297

28 %, 0

28 %, 0.050). exploration. UCBUTUCvaluewith MVAC.[5,6]?III4051000GCMVAC13.8 versus 14.80.75[7]?III85NRNRPaclitaxel + carboplatinMVAC13.8 versus 15.40.65[8]?III2208416Docetaxel + cisplatinDD-MVAC + G-CSF9.3 versus 14.20.026Survival difference was nonsignificant after adjusting for prognostic factors (0.089).[9]?III1308313Dose-dense GC + G-CSFDD-MVAC + G-CSF18.0 versus 19.00.98[10]?III6268213PGCGC15.8 versus 12.70.075[11]?II638318Sunitinib + GC-12-[12]?II987030Sorafenib + GCPlacebo